Homocysteine's role in the causation of presbyopia
Homocysteine's role in the causation of presbyopia
批准号:
6546989
负责人:
CHARLES W PRINCE
金额:
$7.25万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-08-01 至 2005-07-31
关键词:
age difference aging blood chemistry clinical research cryopreservation disease /disorder proneness /risk eye refraction disorder female folate genetic polymorphism genetic susceptibility genotype homocysteine homocystinuria human subject lens miscellaneous oxidoreductase myopia patient oriented research statistics /biometry vision tests vitamin B12 young adult human (21-34)
中文摘要
循环同型半胱氨酸升高是胱硫醚β-合成酶缺乏症(也称为同型半胱氨酸尿症)的主要生化特征,血浆总水平通常超过100微米(正常血浆总水平不超过100微米)。从这种疾病的一系列病理中可以清楚地看到,严重的高同型半胱氨酸血症对结缔组织有显著的有害影响-最常见的与眼睛相关的病理变化是异位晶状体,先于老花眼和严重近视。我们提出的假设是,轻度到中度的高同型半胱氨酸血症是老花眼的危险因素。我们将测量的调节幅度与血浆中总同型半胱氨酸(THcy)水平以及已知与tHcy升高相关的主要遗传多态(5,10-亚甲基四氢叶酸还原酶(MTHFR)、C677T、ALA和GT;VAI)的分布相关联。我们期望在调节幅度低的个体中发现更普遍的异常遗传特征。因此,在这个试点项目中,我们提出了三个具体目标,旨在为R01应用程序提供初步数据支持。具体目的1.招募至少30名年龄在20~39岁的MTHFR纯合子(正常、杂合、突变)受试者,测量其单眼的调节幅度。具体目标2:对于尚未获得下列数据的受试者:a)测定血浆中同型半胱氨酸(THcy)、叶酸和维生素B12的总水平;b)确定受试者的MTHFR不耐热变异体的基因;以及c0存档-70摄氏度的DNA和血浆样本,以供这些研究的未来扩展。具体目的3.统计分析调节幅度与tHcy的相关性。MTHFR基因型与血中叶酸和维生素B12水平;在调整年龄、MTHFR状态、叶酸和维生素B12水平的同时,使用线性回归模型进行多变量分析,以评估tHcy对调节幅度的影响。回归系数的估计和显著性检验将基于t检验和F检验统计。
英文摘要
Elevated circulating homocysteine is the major biochemical feature of cystathionine beta-synthase deficiency (also known as homocystinuria) with total plasma levels usually exceeding 100microM (normal total plasma levels do not exceed 100microM. It is clear from the set of pathologies that occurs in this disorder that severe hyperhomocysteinemia has significant detrimental effects on connective tissues- the most commonly observed pathological changes related to the eye are ectopia lentis preceded by presbyopia and severe myopia. We propose the hypothesis that mild to moderate hyperhomocysteinemia is a risk factor for presbyopia. We shall correlate measured accommodative amplitude with total Hcy (tHcy) levels in plasma (an inverse correlation is expected), and with the distribution of a major genetic polymorphism (5,10-methylenetera-hydrofolate reductase (MTHFR), C677T, Ala > VaI) known to be associated with elevated tHcy. We expect to find the abnormal genetic trait more prevalent among individuals with low accommodative amplitude. In this Pilot Project, we therefore propose three specific aims designed to provide preliminary data supportive of an R01 application. Specific Aim 1. To recruit at least 30 subjects of each MTHFR genotype (homozygous normal, heterozygote, homozygous mutant), aged 20 to 39 years, and measure their accommodative amplitude in one eye. Specific Aim 2: For subjects for whom the following data are not already available, to: a) determine total plasma levels of homocysteine (tHcy), folate and vitamin B12; b) establish the genotype of the participants with regard to the thermolabile variant of MTHFR; and c0 archive of -70 degrees Centigrade the DNA and plasma samples for future extension of these studies. Specific Aim 3. To statistically analyze the results correlating accommodative amplitude to tHcy. MTHFR genotype and blood folate and vitamin B12 levels; to undertake multivariate analysis using the linear regression model to assess the effect of tHcy on accommodation amplitude while adjusting for age, MTHFR status, folate, and vitamin B12 levels. Estimates of regression coefficients and tests of significance will be based on t-test and F-test statistics.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HOMOCYSTEINE MODIFIES BONE MATRIX AND MINERALIZATION
-
批准号:7229902
-
项目类别:
-
资助金额:$14.48万
-
财政年份:2006
-
负责人:CHARLES W PRINCE
-
依托单位:
HOMOCYSTEINE MODIFIES BONE MATRIX AND MINERALIZATION
-
批准号:7024679
-
项目类别:
-
资助金额:$17.34万
-
财政年份:2006
-
负责人:CHARLES W PRINCE
-
依托单位:
HOMOCYSTEINEMIA--A RISK FACTOR FOR OSTEOPOROSIS
-
批准号:3425967
-
项目类别:
-
资助金额:$4.95万
-
财政年份:1993
-
负责人:CHARLES W PRINCE
-
依托单位:
HOMOCYSTEINEMIA--A RISK FACTOR FOR OSTEOPOROSIS
-
批准号:2131706
-
项目类别:
-
资助金额:$2.14万
-
财政年份:1993
-
负责人:CHARLES W PRINCE
-
依托单位:
PROTEOGLYCANS AND OSTEOPONTIN IN BONE FORMATION
-
批准号:3072205
-
项目类别:
-
资助金额:$5.28万
-
财政年份:1988
-
负责人:CHARLES W PRINCE
-
依托单位:
PROTEOGLYCANS AND OSTEOPONTIN IN BONE FORMATION
-
批准号:3072204
-
项目类别:
-
资助金额:$5.44万
-
财政年份:1988
-
负责人:CHARLES W PRINCE
-
依托单位:
BIOCHEMICAL STUDIES OF MINERALIZED TISSUE PROTEOGLYCANS
-
批准号:3220236
-
项目类别:
-
资助金额:$10.93万
-
财政年份:1988
-
负责人:CHARLES W PRINCE
-
依托单位:
BIOCHEMICAL STUDIES OF MINERALIZED TISSUE PROTEOGLYCANS
-
批准号:2129389
-
项目类别:
-
资助金额:$16.75万
-
财政年份:1988
-
负责人:CHARLES W PRINCE
-
依托单位:
PROTEOGLYCANS AND OSTEOPONTIN IN BONE FORMATION
-
批准号:3072207
-
项目类别:
-
资助金额:$6.43万
-
财政年份:1988
-
负责人:CHARLES W PRINCE
-
依托单位:
PROTEOGLYCANS AND OSTEOPONTIN IN BONE FORMATION
-
批准号:3072206
-
项目类别:
-
资助金额:$6.35万
-
财政年份:1988
-
负责人:CHARLES W PRINCE
-
依托单位:
BIOCHEMICAL STUDIES OF MINERALIZED TISSUE PROTEOGLYCANS
-
批准号:2129387
-
项目类别:
-
资助金额:$18.87万
-
财政年份:1988
-
负责人:CHARLES W PRINCE
-
依托单位:
BIOCHEMICAL STUDIES OF MINERALIZED TISSUE PROTEOGLYCANS
-
批准号:3220235
-
项目类别:
-
资助金额:$9.89万
-
财政年份:1988
-
负责人:CHARLES W PRINCE
-
依托单位:
BIOCHEMICAL STUDIES OF MINERALIZED TISSUE PROTEOGLYCANS
-
批准号:2129388
-
项目类别:
-
资助金额:$16.03万
-
财政年份:1988
-
负责人:CHARLES W PRINCE
-
依托单位:
PROTEOGLYCANS AND OSTEOPONTIN IN BONE FORMATION
-
批准号:3072203
-
项目类别:
-
资助金额:$5.44万
-
财政年份:1988
-
负责人:CHARLES W PRINCE
-
依托单位:
BIOCHEMICAL STUDIES OF MINERALIZED TISSUE PROTEOGLYCANS
-
批准号:3220233
-
项目类别:
-
资助金额:$10.06万
-
财政年份:1984
-
负责人:CHARLES W PRINCE
-
依托单位:
BIOCHEMICAL STUDIES OF MINERALIZED TISSUE PROTEOGLYCANS
-
批准号:3220231
-
项目类别:
-
资助金额:$18.31万
-
财政年份:1984
-
负责人:CHARLES W PRINCE
-
依托单位:
BIOCHEMICAL STUDIES OF MINERALIZED TISSUE PROTEOGLYCANS
-
批准号:3447064
-
项目类别:
-
资助金额:$4.67万
-
财政年份:1984
-
负责人:CHARLES W PRINCE
-
依托单位:
BIOCHEMICAL STUDIES OF MINERALIZED TISSUE PROTEOGLYCANS
-
批准号:3220234
-
项目类别:
-
资助金额:$7.73万
-
财政年份:1984
-
负责人:CHARLES W PRINCE
-
依托单位:
BIOCHEMICAL STUDIES OF MINERALIZED TISSUE PROTEOGLYCANS
-
批准号:3447065
-
项目类别:
-
资助金额:$4.99万
-
财政年份:1984
-
负责人:CHARLES W PRINCE
-
依托单位:
BIOCHEMISTRY OF MINERALIZED TISSUE PROTEOGLYCANS; BONE; VIT; IN VIVO
-
批准号:3871682
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:CHARLES W PRINCE
-
依托单位:
海外基金